NAD+-dependent 15-hydroxyprostaglandin dehydrogenase regulates levels of bioactive lipids in non-small cell lung cancer.

Cancer Prevention Research
Duncan HughesAndrew J Dannenberg

Abstract

Elevated levels of procarcinogenic prostaglandins (PG) are found in a variety of human malignancies including non-small cell lung cancer (NSCLC). Overexpression of cyclooxygenase-2 and microsomal prostaglandin synthase 1 occurs in tumors and contributes to increased PG synthesis. NAD+-dependent 15-hydroxyprostaglandin dehydrogenase (15-PGDH), the key enzyme responsible for metabolic inactivation of PGs, is down-regulated in various malignancies. The main objective of this study was to elucidate the effect of loss of 15-PGDH on levels of bioactive lipids in NSCLC. We found that levels of cyclooxygenase-2 and microsomal prostaglandin synthase 1 were commonly increased whereas the amount of 15-PGDH was frequently decreased in NSCLC compared with adjacent normal lung. Reduced expression of 15-PGDH occurred in tumor cells and was paralleled by decreased 15-PGDH activity in tumors. Amounts of PGE1, PGE2, and PGF(2alpha), known substrates of 15-PGDH, were markedly increased whereas levels of 13,14-dihydro-15-keto-PGE2, a catabolic product of PGE2, were markedly reduced in NSCLC compared with normal lung. Complementary in vitro and in vivo experiments were done to determine whether these changes in PG levels were a consequence of down-...Continue Reading

References

Feb 14, 1970·Nature·P J PiperJ H Wyllie
Dec 1, 1982·British Journal of Cancer·A BennettF Williams
Oct 1, 1995·Journal of Lipid Mediators and Cell Signalling·C M Ensor, H H Tai
Feb 1, 1996·Prostaglandins, Leukotrienes, and Essential Fatty Acids·A Lupulescu
Feb 1, 1997·Human Genetics·F PichaudM F Rousseau-Merck
Jun 23, 1999·Proceedings of the National Academy of Sciences of the United States of America·P J JakobssonB Samuelsson
Dec 22, 1999·The Journal of Immunology : Official Journal of the American Association of Immunologists·M StolinaS M Dubinett
Jun 30, 2000·The New England Journal of Medicine·G SteinbachG Kelloff
Aug 31, 2000·Annual Review of Biochemistry·W L SmithR M Garavito
Sep 28, 2000·Biochemical and Biophysical Research Communications·M Tong, H H Tai
Nov 16, 2002·Prostaglandins & Other Lipid Mediators·Hsin-Hsiung TaiFengxiang Yan
Jul 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N K AltorkiA J Dannenberg
Jan 7, 2004·Cancer Cell·Andrew J Dannenberg, Kotha Subbaramaiah
Nov 16, 2004·The Journal of Biological Chemistry·Michael G BacklundRaymond N DuBois
Dec 3, 2004·Proceedings of the National Academy of Sciences of the United States of America·Min YanSanford D Markowitz
Dec 22, 2004·Journal of Gastroenterology and Hepatology·Emilio SiendonesJordi Muntané
Aug 2, 2006·Proceedings of the National Academy of Sciences of the United States of America·Seung-Jae MyungSanford D Markowitz
Aug 4, 2006·Cancer Research·Ido WolfH Phillip Koeffler
Sep 1, 2006·Circulation·Scott D SolomonUNKNOWN APC and PreSAP Trial Investigators
Sep 1, 2006·The New England Journal of Medicine·Monica M BertagnolliUNKNOWN APC Study Investigators
Oct 3, 2006·Prostaglandins, Leukotrienes, and Essential Fatty Acids·Peiying YangRobert A Newman
Feb 13, 2007·Journal of Molecular and Cellular Cardiology·Christoph GenschUlrich Laufs
Apr 18, 2007·International Journal of Cancer. Journal International Du Cancer·David QualtroughChristos Paraskeva
Feb 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martin J EdelmanMark J Green

❮ Previous
Next ❯

Citations

Oct 19, 2011·Cancer Metastasis Reviews·Ashleigh E MooreDan A Dixon
Oct 25, 2011·Cancer Metastasis Reviews·Hsin-Hsiung Tai
Feb 20, 2010·Nature Reviews. Cancer·Dingzhi Wang, Raymond N Dubois
Jul 18, 2009·American Journal of Physiology. Gastrointestinal and Liver Physiology·Akira MiyakiAndrew J Dannenberg
Apr 27, 2012·Journal of Lipid Research·Yang-Yi FanRobert S Chapkin
May 15, 2012·Progress in Lipid Research·Inês Cebola, Miguel A Peinado
May 9, 2012·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Mirjam GnadtPetra Högger
Aug 26, 2011·Prostaglandins & Other Lipid Mediators·Emily R GreeneDipak Panigrahy
Jan 23, 2010·The American Journal of Pathology·Stephanie Tseng-RogenskiMonica Liebert
Nov 11, 2008·Gastroenterology·Scott M Lippman
Feb 13, 2018·Cancer Chemotherapy and Pharmacology·Liboria SienaElisabetta Pace
Jan 1, 2011·Cancers·Dingzhi WangRaymond N Dubois
Jan 15, 2015·The Journal of Biological Chemistry·Stacy Gelhaus WendellBruce A Freeman
May 5, 2009·Expert Opinion on Therapeutic Targets·Leora HornDavid H Johnson
Jul 25, 2014·The Journal of Immunology : Official Journal of the American Association of Immunologists·Yan LiFeng Lin
Aug 6, 2019·Frontiers in Pharmacology·Meike J SaulBeatrix Suess
Jan 14, 2009·Cancer Prevention Research·Steven M DubinettSaswati Hazra
Jun 25, 2016·Cancer Prevention Research·Yang-Yi FanRobert S Chapkin
Dec 29, 2020·Frontiers in Pharmacology·Amber M JohnsonRaphael A Nemenoff
Mar 11, 2020·Prostaglandins, Leukotrienes, and Essential Fatty Acids·Hiroaki ShimadaMasahiro Iwaki

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Metabolism

In order for cancer cells to maintain rapid, uncontrolled cell proliferation, they must acquire a source of energy. Cancer cells acquire metabolic energy from their surrounding environment and utilize the host cell nutrients to do so. Here is the latest research on cancer metabolism.

Cancer Metabolic Reprogramming (Keystone)

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

Cancer Metabolic Reprogramming

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

© 2021 Meta ULC. All rights reserved